Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

biOasis to Present at the 2013 Gateway Conference on September 10

Marketwired September 4, 2013

biOasis Technologies Inc. Announces Notice of Allowance for Key Lysosomal Storage Disease Patent From the US Patent and Trademark Office

Marketwired August 7, 2013

CEO Letter to Shareholders

Marketwired June 18, 2013

CEO Letter to Shareholders

Marketwired June 18, 2013

biOasis's Update on the BT2111-Herceptin(R) Program

Marketwired April 9, 2013

biOasis Named to 2013 TSX Venture 50(R)

MarketWire Canada February 13, 2013

biOasis Announces Positive Anti-Tumour Efficacy Data

MarketWire Canada February 7, 2013

Stockhouse @ the Bell: Stocks up on Greek debt latest

Stockhouse Editorial February 8, 2012

Gold's best year yet? Best of the Boards/Blogs

Stockhouse Editorial February 8, 2012

Junior explorer jumps on resource update announcement

Sean Mason July 6, 2011